Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00158561
Other study ID # ITDCKD45
Secondary ID
Status Completed
Phase Phase 3
First received September 9, 2005
Last updated January 11, 2017
Start date February 2004
Est. completion date March 2006

Study information

Verified date January 2017
Source London School of Hygiene and Tropical Medicine
Contact n/a
Is FDA regulated No
Health authority Pakistan: Ministry of HealthAfghanistan: Ministry of Public Health
Study type Interventional

Clinical Trial Summary

To determine whether two cheap antifolates (chlorproguanil-dapsone and sulfadoxine-pyrimethamine) which work against falciparum malaria in this region are sufficiently effective against vivax malaria to be deployed in areas where diagnosis is poor and the burden of malaria is high, a randomised controlled trial of the three drugs is being undertaken comparing their efficacy in treating malaria.


Description:

Objectives:

Primary:

To evaluate the comparative efficacy of chlorproguanil / dapsone with sulfadoxine-pyrimethamine for the treatment of vivax malaria in Pakistan and eastern Afghanistan.

Secondary:

- To compare the efficacy of chlorproguanil-dapsone and sulfadoxine-pyrimethamine with chloroquine

- To evaluate the safety profile of chlorproguanil / dapsone in south Asians from this region when used for the treatment of vivax malaria.

- To evaluate the effect of chlorproguanil / dapsone on gametocyte clearance rates.

- To evaluate the effect of chlorproguanil / dapsone on subsequent relapse due to vivax malaria.

Study Population:

750 P.vivax positive individuals recruited from the Malaria Reference Centre in Jalalabad, Afghanistan and at health facilities in Afghan refugee camps in North West Frontier Province (NWFP), Pakistan supervised by HealthNet International

Efficacy Parameters :

Primary Efficacy Variable:

• Day 14 slide clearance rate (complete clearance of parasites), assessed by microscopists who are blind to treatment allocation. Slides will be double read.

Secondary Efficacy Variables

- Day 28 slide clearance rate defined as the number of treated patients with clearance of parasitaemia within 14 days of starting treatment, without subsequent recrudescence up to day 28.

- Day 14 clinical failure rate (presence of symptoms of malaria in the presence of parasitaemia).

- Day 28 clinical failure rate.

- Adverse events.

- Haemoglobin level increased by at least 1g/dl by day 14.

- Clearance of gametocytaemia by day 3, 7, and 14.

- Number of subsequent malaria episodes in next 6 months. It is assumed that the population of each treatment arm is equally likely to be re-infected in this time scale. Therefore any measurable difference in number of subsequent episodes between treatment arms will be due to a relapse.

- In G6PD deficient patients the change in mean haemoglobin.

Safety Parameters:

Adverse events and laboratory findings will be monitored in all patients. Regular haemoglobin to identify haemolysis.

Study design:

Recruitment and administration:

Recruitment and administration of all treatments will be directly observed by the trial coordinator and trial pharmacist, and/or health unit clinician.

Dosing Schedules:

Chlorproguanil-dapsone (Lapdap): (target doses 2.0 and 2.5 mg/kg respectively) daily for 3 days .

Sulfadoxine - pyrimethamine (SP): (target doses 1.25 and 25.0 mg/kg respectively) once only.

Chloroquine (CQ): (target dose 25mg/kg ) daily for 3 days.

Follow up:

Patients will return to the clinic on days 0, 1, 2, 3, 7, 14, 21 and 28 for supervised dosing, thick and thin smears, blood spot filter papers, update of clinical record forms, determination of haemoglobin, full blood cell counts, liver function tests, determination of adverse events and concomitant medication details, as appropriate.


Recruitment information / eligibility

Status Completed
Enrollment 750
Est. completion date March 2006
Est. primary completion date
Accepts healthy volunteers No
Gender All
Age group 3 Years and older
Eligibility Inclusion Criteria:

1. Presentation at BHU or clinic with probable clinical malaria.

2. Infection with P. vivax, confirmed by microscopy.

3. Age 3 years or older (no restriction on upper age limit).

4. Written or witnessed verbal consent obtained from the patient or the patients parent or guardian.

5. Married women of child bearing age confirmed to be non-pregnant at outset and willing to remain thus for the duration of the study.

6. Willingness to comply with the requirements of the protocol and particularly to provide venous and thumb prick blood samples.

7. Available for follow up for the duration of the study and not less than 6 months.

8. Willingness to report to the BHU or clinic if they feel unwell in the 6 months following completion (i.e. 7 months from enrolment date). NB these patients will only be those recruited up to 7 months before the end of the study period.

9. Availability of G6PD status by willingness to be tested at admission.

Exclusion Criteria:

1. General condition requiring hospital admission.

2. Evidence of any concomitant infection likely to mask treatment response at the time of presentation.

3. Presence of any other underlying disease that compromises the diagnosis and the evaluation of the response to the study medication.

4. History of allergy to sulphonamides, dapsone or chloroquine or hypersensitivity to biguanides (eg proguanil, chlorproguanil) sulphones (eg frusemide, thiazides, acetazolamide, and sulphonylureas) or any other tablet contents.

5. Known methaemoglobin reductase deficiency and haemoglobin M.

6. Treatment within the past twenty-eight days with sulfadoxine/pyrimethamine (Fansidar), sulfalene/pyrimethamine (Metakelfin), mefloquine-sulfadoxine-pyrimethamine (Fansimef); 21-days with mefloquine, or 7-days with amodiaquine, chloroquine, halofantrine, quinine (full course), primaquine, atovaquone - proguanil, artemisinin derivatives, co-artemether, trimethoprim, chloramphenicol, erythromycin, tetracycline or clindamycin.

7. Visible jaundice.

8. Use of an investigational drug within 30 days or 5 half-lives whichever is the longer.

9. Severe anaemia (Hb<7 g/dl).

10. Other species of malaria seen.

11. Pregnancy, assessed by pregnancy test in all married women of child-bearing age (age over 14 and under 50).

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label


Related Conditions & MeSH terms


Intervention

Drug:
sulfadoxine-pyrimethamine and chlorproguanil-dapsone


Locations

Country Name City State
Pakistan HealthNet International Peshawar

Sponsors (2)

Lead Sponsor Collaborator
London School of Hygiene and Tropical Medicine HealthNet TPO

Country where clinical trial is conducted

Pakistan, 

References & Publications (1)

Leslie T, Mayan MI, Hasan MA, Safi MH, Klinkenberg E, Whitty CJ, Rowland M. Sulfadoxine-pyrimethamine, chlorproguanil-dapsone, or chloroquine for the treatment of Plasmodium vivax malaria in Afghanistan and Pakistan: a randomized controlled trial. JAMA. 2 — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Day 14 slide clearance rate (complete clearance of parasites), assessed by microscopists who are blind to treatment allocation.
Secondary Day 28 slide clearance rate defined as the number of treated patients with clearance of parasitaemia within 14 days of starting treatment, without subsequent recrudescence up to day 28.
Secondary Day 14 clinical failure rate (presence of symptoms of malaria in the presence of parasitaemia).
Secondary Day 28 clinical failure rate.
Secondary Adverse events.
Secondary Haemoglobin level increased by at least 1g/dl by day 14.
Secondary Clearance of gametocytaemia by day 3, 7, and 14.
Secondary Number of subsequent malaria episodes in next 6 months. It is assumed that the population of each treatment arm is equally likely to be re-infected in this time scale. Therefore any measurable difference in number of subsequent episodes between treatment
Secondary In G6PD deficient patients the change in mean haemoglobin.
See also
  Status Clinical Trial Phase
Completed NCT04601714 - Baseline Cohort Malaria Morbidity Study
Withdrawn NCT04020653 - A Study to Assess the Safety and Efficacy of 5-aminolevulinic Acid Hydrochloride (5-ALA HCl) and Sodium Ferrous Citrate (SFC) Added on Artemisinin-based Combination Therapy (ACT) in Adult Patients With Uncomplicated Malaria Phase 2
Terminated NCT04368910 - Safety and Efficacy of Pyronaridine Artesunate Vs Chloroquine in Children and Adult Patients With Acute Vivax Malaria Phase 3
Completed NCT03641339 - Defining Skin Immunity of a Bite of Key Insect Vectors in Humans N/A
Completed NCT02544048 - Markers of T Cell Suppression: Antimalarial Treatment and Vaccine Responses in Healthy Malian Adults
Completed NCT00527163 - Role of Nitric Oxide in Malaria
Not yet recruiting NCT05934318 - L-ArGinine to pRevent advErse prEgnancy Outcomes (AGREE) N/A
Active, not recruiting NCT04704674 - Community Dynamics of Malaria Transmission in Humans and Mosquitoes in Fleh-la and Marshansue, Salala District, Bong County, Liberia
Completed NCT03276962 - Efficacy, Safety and Immunogenicity Study of GSK Biologicals' Candidate Malaria Vaccine (SB257049) Evaluating Schedules With or Without Fractional Doses, Early Dose 4 and Yearly Doses, in Children 5-17 Months of Age Phase 2
Completed NCT04966871 - Safety, Tolerability and Efficacy of PfSPZ Vaccine Against Heterologous CHMI in US Malaria naïve Adults Phase 1
Completed NCT00289185 - Study of Safety, Immunogenicity and Efficacy of a Candidate Malaria Vaccine in Tanzanian Infants Phase 2
Recruiting NCT03937817 - Collection of Human Biospecimens for Basic and Clinical Research Into Globin Variants
Active, not recruiting NCT06153862 - Africa Ready Malaria Screening N/A
Completed NCT04545905 - Antenatal Care as a Platform for Malaria Surveillance: Utilizing Community Prevalence Measures From the New Nets Project to Validate ANC Surveillance of Malaria in Burkina Faso
Recruiting NCT06278181 - Diabetes, Metabolic Syndrome and Risk of Malaria in Cameroon
Completed NCT02793622 - Prevention of Malaria in HIV-uninfected Pregnant Women and Infants Phase 3
Completed NCT02909712 - Cardiac Safety of Dihydroartemisinin-Piperaquine Amongst Pregnant Women in Tanzania Phase 2
Withdrawn NCT02793414 - Diagnostic Utility of Volatile Organic Compounds in Human Breath for Acute Clinical Malaria in Ethiopia
Withdrawn NCT02793388 - A Trial on Supervised Primaquine Use in Ethiopia Phase 4
Completed NCT02536222 - Accelerating the Reduction of Malaria Transmission in Kanel, Ranérou and Linguère Districts Phase 4